Growth Company Investor - Stock market recommendations on AIM and small cap companies

28 July 2014

Norwood Immunology loses £2.3m 13/10/2005

Australia-based Norwood Immunology cut its loss from £3.1 million to £2.3 million last year and is pursuing collaboration deals.

Drug floats drying up 02/08/2004

The City's appetite for backing new biotech concerns is diminishing. Recently, cancer therapeutics researcher Cyclacel cancelled its flotation, which had been mooted to raise 26 million. This would have valued the company at 110 million.

Tech watch - by Elliott Davis 01/06/2004

The biotech market is rising after a long period of depression, but heady valuations are still raising eyebrows.

What moves small-cap share prices?

A research report into the top-performing 100 companies below the FTSE 350 and on AIM. Click here to download.

Cash Shells 2014

This annual guide provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. The guide is available to pre-order for £295 (+VAT). More info

 

The Growth of Activist Investing in Europe, London

The Growth of Activist Investing in Europe taking place on June 2 in London will educate European company management on how to position themselves as this trend continues to grow. Register here.

Directors' Pay on AIM 2014

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1,044 AIM-quoted companies. The full report is available to order for £365 + VAT. Click here for more info

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

What Investment magazine: save 45% on the shop price

Be the first to receive our independent analysis and research, designed to help you generate more wealth for you and your family over the long term. Subscribe and save.

Popular Topics